ARJUNA FLOW II
Natural health product licensed in Canada
- Licence holder
- Advanced Orthomolecular Research Inc.
- NPN or DIN-HM
- 80089450
- Status
- Active licence
- Licence date
- 6 December 2018
- Revision date
- Not provided
- Form
- Poudre
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Terminalia arjuna Source : Écorce (tige) Extract : Matériel brut sec Extraction ratio : 9:1 Dry plant equivalent : 4,500 mg | 500 mg | Not calculated |
| Hibiscus sabdariffa Source : Sépale Extract : Matériel brut sec Extraction ratio : 12:1 Dry plant equivalent : 18 g | 1,500 mg | Not calculated |
| Crataegus monogyna Source : New material Extract : Matériel brut sec Extraction ratio : 4.5:1 Dry plant equivalent : 900 mg | 200 mg | Not calculated |
Non-medicinal ingredients
Saveur de pomme, Saveur de lime, Saveur de fraise, Saveur d'orange, Silice, Maltodextrine, Saveur d'ananas
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Portion(s) | minimum: 1 day ; maximum: 2 days |
Uses authorised in Canada
Source of antioxidants/Provides antioxidants. Source of antioxidants/Provides antioxidants that help fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals. Used in herbal medicine to help maintain and/or support cardiovascular health in adults. Terminalia Arjuna is traditionally in Ayurveda as a cardiotonic.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are taking cardiac glycosides such as digitalis/digoxin, or blood pressure medication. If you are breastfeeding, consult a health care practitioner prior to use. If you have a cardiovascular disorder, consult a health care practitioner prior to use. Gastrointestinal discomfort and headache have been known to occur; in which case, discontinue use.
Source
Official Health Canada record, licence 80089450
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.